

Souza BF<sup>1,2</sup>, Molfetta GA<sup>2</sup>, Dinarti-santos AR<sup>2</sup>, Marquez AA<sup>2</sup>, Júnior WAS<sup>1,2</sup>, Ferraz VEF<sup>1</sup>

<sup>1</sup>Department of Genetics, Medical School of Ribeirão Preto-University of São Paulo, Brazil



<sup>2</sup>National Institute of Science and Technology in Stem Cell and Cell Therapy (INCTC), Center for Cell Therapy (CTC), Regional Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.

b\_fs7@hotmail.com

## INTRODUCTION

Clinically there are two groups of prostate cancer: one that remains confined to the prostate, relatively indolent, and metastatic and other that eventually culminates in death. Emerging data confirm that recurrent chromosomal rearrangements may be driven by nuclear transcription factors such as the ligand-bound androgen receptor in prostate cancer. Half of prostate cancers harbor gene fusions between androgen-regulated genes *TMPRSS2* and members of the ETS transcription factor family. African-American, Caucasian, and Oriental populations have this fusion in a frequency ranging from 40 to 70%, and some had their isoforms (fig.1) associated with increased aggressiveness of the tumor (higher Gleason score, early recurrence of PSA, and seminal vesicle invasion). Given the high incidence of PCa in Brazil and in view of its population diversity would be extremely important to know the prevalence and level of expression this rearrangement in this population.


## METHODS



**Figure 1.** *TMPRSS2/ERG* fusions mRNAs in prostate cancer. A, schematic structure of *TMPRSS2/ERG* fusion mRNAs types I to IV. Exons (boxes) for *TMPRSS2* (blue) and *ERG* (purple) are numbered according to Genbank reference sequences (NM\_005656 and NM\_004449). Numbers above the exons, last base of each exon; vertical red arrow, native ATG; hatch marks, longest open reading frame. For each type of fusion, numbers above the fusion site are the last base pair in *TMPRSS2* and the first base pair in *ERG* gene. Insets, position and automated DNA sequencing of the fusion sites, with the *ERG* sequence underlined. Horizontal arrow, first in-frame translation initiation site; its location in the *ERG* gene is shown. Red, translations from native ATGs; green, translations from nonnative ATGs. B, schematic structure of *TMPRSS2/ERG* fusion mRNAs types V to VIII. Fusion mRNAs are illustrated as described above. Red vertical arrows, position of the out-of-frame native *TMPRSS2* ATG; black horizontal arrow, first in-frame ATG in the *ERG* gene; horizontal red arrow, *TMPRSS2/ERG* fusion protein initiation site in the type VI mRNA (Wang, J. et al. 2006).


## RESULTS AND DISCUSSION

Of the total 20 patients assessed, the fusion was present in 35% of cases (Fig. 2), all belonging to type III fusion mRNA (Fig. 3).



**Figure 2.** RT-PCR amplification of *TMPRSS2/ERG* fusion transcripts in prostate cancer. No 01, 08, 09, 12, 14, 15 and 18 are representative for single fusion RT-PCR products type III.

This finding is in agreement with previous studies performed in other populations that found this class of fusion in a greater percentage of cases. This isoform expressed a hybrid protein predicted to be shorter than the protein *ERG* not fused by 39 aminoacids residues. It occurs because this isoform contains the translation initiation in an internal non-native ATG codon of the gene *ERG*.



**Figure 3** - Schematic representation of the sequence of the gene rearrangement *TMPRSS2/ERG* belonging to type III isoform. Shows the region that binds the primer, represented by the black line, and the region of fusion between exon 1 of *TMPRSS2* and *ERG* exon 4, represented by the line in red. Blue box, internal ATG; blue line first in-frame ATG in the *ERG* gene. Suspension points continuation of exons of the gene *ERG* isoform present in type III.

Thus, these proteins have a reduced or modified biological activity, which is associated with a less aggressive tumor phenotype than other isoforms, such as type I, II and VI, which contains a native *ERG* ATG start codon (Fig.3). The analysis of the remaining patients and the level of expression of these isoforms by RT-PCR is the next stage of the project seeking more knowledge that supports the hypothesis of correlation between the isoforms of fusion *TMPRSS2/ERG* with clinical aggressiveness of prostate cancer and its prevalence.

## Conclusion

So far there is an interesting frequency of rearrangement in the study population, indicating that early detection of these rearrangements in admixed populations such as Brazilian population is a good prediction of the prognosis of PCa that can be extremely useful in the clinical management of these patients.

SUPPORTED BY

